Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
Clinical trial NCT05142865 · UNKNOWN
Trial details
- NCT number
- NCT05142865
- Sponsor
- Huazhong University of Science and Technology
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-14
- Primary completion
- 2024-01-14
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.